Mod­er­na inks deal for over­seas Covid-19 vac­cine fin­ish­ing work as Eu­ro­pean ap­proval hangs in bal­ance

De­spite a lack of for­mal ap­proval from the Eu­ro­pean Med­i­cines Agency, Mod­er­na is mov­ing to nail down pro­duc­tion ca­pac­i­ty for the dos­es of its mR­NA-based Covid-19 vac­cine that will be jabbed in­to arms out­side of the U.S.

Just be­fore the new year, Mod­er­na inked a deal with Re­ci­pharm, the Swedish CD­MO, for for­mu­lat­ing and fill-fin­ish work on an undis­closed por­tion of Mod­er­na’s vac­cine sup­ply out­side of the US at Re­ci­pharm’s drug prod­uct man­u­fac­tur­ing fa­cil­i­ty lo­cat­ed in France.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.